Sales projections: What is the expected Lipitor revenue path over 5-10 years under generic price compression? Featured snippet answer: Lipitor sales over the next decade are expected to track a declining brand share multiplied by net price that continues to compress toward generic equivalents, while total atorvastatin class demand is broadly … Humira, introduced by AbbVie in 2003, is expected to remain the drug with the highest lifetime revenue through 2024. Keytruda follows with a lifetime revenue of 213 billion U.S. dollars. Annual Sales of Lipitor reported using PharmaCompass' compilation of Annual Reports of Global Pharmaceutical Companies. Annual pharmaceutical drug sales This is a list of annual sales of patented medications per pharmaceutical group. Because it derives from 10-K data, drugs that have passed loss of exclusivity (LOE) will cease to be on this list. What were Lipitor (atorvastatin) sales by year? I don't have the year-by-year Lipitor sales figures in the information provided here, so I can't produce an accurate table "by year" without pulling from a specific sales dataset or filings source. Worldwide revenue of Pfizer's Lipitor from 2003 to 2019 (in million U.S. dollars) Pfizer's Lipitor revenue worldwide 2003-2019 Overview of the Atorvastatin Industry 2026-2032 Atorvastatin Market size was valued at $ 0.089 Billion in 2026 & is estimated to reach $ 0.15 Billion by 2032, exhibiting a CAGR of 7.71% from 2026-2032. The Atorvastatin market represents a critical segment within the broader cardiovascular therapeutics landscape, primarily driven by its pivotal role in managing hypercholesterolemia and reducing … LIPITOR Market size is expected to reach USD 937.7 Mn by 2033 from USD 1,386.6 Mn in 2026, exhibiting a CAGR of -5.2% during the forecast period 2026-2033 Counting up 25 years' worth of sales, Pfizer's Lipitor remains the U.S.' best-selling drug over the past two and a half decades, but AbbVie's Humira will soon catch up. (Pixabay/CC0) Take a look … Pfizer will undoubtedly feel the loss of Lipitor sales. It has been planning for this schismatic change for several years. In the past, the company has claimed that it can maintain huge research and development expenditures despite the increasing rarity of new blockbuster drugs. But this year it has already announced closure of its research site at Sandwich, Kent, UK, let go of most of its … Lipitor, the cholesterol-lowering medication that has become the gold standard of statins, continues to generate roughly $2 billion per year in sales for Pfizer, even though its patent expired eight years ago. The big picture: Almost all of Pfizer's Lipitor sales now come from China and other emerging markets. But Lipitor's ability to remain a blockbuster drug, even with so many generic … A striking graph of those results helped Lipitor sales representatives turn it into the world's best-selling drug ever, with more than $125 billion in sales over 14 1/2 years. Apache/2.4.52 (Ubuntu) Server at fomatmedical.com Port 80 A Sales Record That Belongs in the Past For years, Lipitor was the best-selling drug in the history of the pharmaceutical industry. In 2020, AbbVie's Humira finally overtook it. By the end of that year, Humira's cumulative sales had reached US$172.1 billion, compared with US$161.9 billion for Lipitor since its launch (Hardman & Co). Lipitor was approved by the government in 1997, and while under patent protection it was the highest-selling drug of all time with worldwide sales of more than US$12 billion a year. Assessing the industry's biggest ever products by lifetime sales, rather than peak annual performance, further confirms the status of Pfizer's Lipitor as the most commercially successful drug of all time. Over the course of its lifetime, Lipitor has generated global sales of $141 billion – nearly double that of its closest competitor in the list, Bristol-Myers Squibb and Sanofi's Plavix … Atorvastatin calcium is a widely prescribed lipid-lowering medication belonging to the statin class of drugs. It is primarily used to reduce low-density lipoprotein (LDL) cholesterol and triglyceride levels while increasing high-density lipoprotein (HDL) cholesterol, thereby helping to lower the risk of cardiovascular diseases, such as heart attacks and strokes. Two new generic brands of cholesterol-lowering medication threaten sales to Pfizer's number one selling drug — Lipitor. Good news? More people can afford it now. Explore the best-selling drugs US pharma produced over 25 years, from Lipitor to Humira, and what clinical research made each blockbuster possible. The drug's name: Lipitor, which went off patent and began facing generic competition December 1, 2011. That's right, Lipitor, once the world's biggest selling drug – peaking at annual … The sales force further supported the Lipitor campaign through the distribution of free product samples. Warner-Lambert and Pfizer implemented an aggressive sampling program, distributing 7.3 million samples to physicians in the first year of launch for a share of voice of slightly over 23%. A striking graph of those results helped Lipitor sales representatives turn it into the world's best-selling drug ever, with more than $125 billion in sales over 14.5 years. Checking your browser before accessing pmc.ncbi.nlm.nih.gov … Over the past decade, Lipitor was the most widely used branded prescription treatment for lowering blood cholesterol levels. Global Lipitor sales peaked at $13 billion in 2006 and has been on a … LIPITOR is indicated: To reduce the risk of: As an adjunct to diet to reduce low-density lipoprotein cholesterol (LDL-C) in: As an adjunct to other LDL-C-lowering therapies, or alone if such treatments are unavailable, to reduce LDL-C in adults and pediatric patients aged 10 years and older with homozygous familial hypercholesterolemia (HoFH). Atorvastatin drug usage statistics for the United States (2014 – 2024). Statistics include drug synonyms and therapeutic classes, including: Atorvastatin Calcium, Atorvastatin Calcium Anhydrous, Atorvastatin Calcium Propylene Glycol Solvate, Atorvastatin Calcium Trihydrate, Atorvastatin, Atorvaliq, Lipitor, HMG-CoA Reductase Inhibitor. Lipitor redefined the statin category, achieved record prescription volumes, and set a durable benchmark for cardiovascular brand leadership after its 1997 launch. Pfizer, founded in 1849, combined scientific strength and disciplined commercialization to build the world's most recognized cholesterol brand. Marketing strategy amplified clinical differentiation, simplified risk communication … Pfizer's cholesterol drug Lipitor was the top global drug for years in the 2000s but yielded its position due to heavy losses caused, once again, by patent expiration. Atorvastatin is a statin medication used to lower cholesterol levels in the blood. It was originally developed by Pfizer and is commonly sold under the brand name Lipitor. Atorvastatin (Lipitor & others): Atorvastatin accounts for 41% of the statin market and remains the most prescribed molecule worldwide. Lipitor became a landmark cardiovascular product, and generic versions entered after patent expiry, widening access in both developed and emerging economies. Rising brand-name pharmaceutical expenditures can be significantly mitigated with generic substitution, particularly for high-volume categories, such as statins. 1, 2 Pfizer's Lipitor (atorvastatin calcium) was the best-selling drug of all time until a generic version became available in the United States in November 2011. 3 However, national use of Lipitor and the financial impact of … A striking graph of those results helped Lipitor sales representatives turn it into the world's best-selling drug ever, with more than $125 billion in sales over 14 ½ years. How do peak sales compare with other big statins? Compared with other statins of its era, Lipitor is widely cited as the top-selling brand statin at its height, with peak revenue around the $10 billion/year range, outpacing many competitors. Does DrugPatentWatch.com track Lipitor's patent/exclusivity timeline? Recent years have seen significant advancements and shifts in the therapeutic approaches to one of the world's leading health concerns: cardiovascular diseases. As we delve into the top 15 cardiovascular disease drugs in 2023, guided by comprehensive 2022 sales data, we gain valuable insights into the market trends, drug efficacy and the evolving needs of patients worldwide. For healthcare … Whether peak annual Humira sales will ever reach the Lipitor benchmark is open to conjecture. Current consensus forecasts indicate that sales of the anti-TNF product will peak at around $11.2 … LIPITOR is indicated: To reduce the risk of: As an adjunct to diet to reduce low-density lipoprotein cholesterol (LDL-C) in: As an adjunct to other LDL-C-lowering therapies, or alone if such treatments are unavailable, to reduce LDL-C in adults and pediatric patients aged 10 years and older with homozygous familial hypercholesterolemia (HoFH).